MedTrace Logo

Occluded Artery Trial (OAT)

NCT00004562 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2201

Last updated 2014-04-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether opening an occluded infarcted artery 3-28 days after an acute myocardial infarction in high-risk asymptomatic patients reduces the composite endpoint of mortality, recurrent myocardial infarction, and hospitalization for class IV congestive heart failure over an average 2.9-year follow-up with extended follow up for an average of six years. Long term follow-up of patients were completed in March 2010. Final collection of all regulatory documentation was completed June 2011.

Conditions

Interventions

DRUG

Beta adrenergic blockers

Participants will receive beta adrenergic blockers.

DRUG

Platelet inhibitors

Participants will receive platelet inhibitors.

PROCEDURE

PTCA and stents

Participants will undergo percutaneous coronary intervention (PTCA) and coronary stenting.

DRUG

ACE Inhibitors

Participants will receive ACE inhibitors.

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • NYU Langone Health

    lead OTHER

Principal Investigators

  • Judith S. Hochman, M.D. · NYU Langone Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-09-30
Primary Completion
2010-03-31
Completion
2011-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004562 on ClinicalTrials.gov